X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2023/03/21/2631168/0/en/Intellia-Therapeutics-Announces-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-Granted-to-NTLA-2002-for-the-Treatment-of-Hereditary-Angioedema.html
https://endpts.com/intellia-gets-fda-clearance-to-start-hereditary-angioedema-gene-editing-trial-in-us/
https://www.globenewswire.com/news-release/2023/03/02/2619120/0/en/Intellia-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-IND-Application-for-NTLA-2002-an-In-Vivo-CRISPR-Based-Investigational-Therapy-for-the-Treatment-of-Heredit.html
https://www.fiercebiotech.com/biotech/novartis-pulls-back-legacy-sickle-cell-program-intellia-ceo-calls-market-wide-open
https://www.globenewswire.com/news-release/2023/02/23/2614167/0/en/Intellia-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html
https://www.globenewswire.com/news-release/2023/02/16/2609595/0/en/Intellia-Therapeutics-to-Hold-Conference-Call-to-Discuss-Fourth-Quarter-and-Full-Year-2022-Earnings-and-Company-Updates.html
https://www.globenewswire.com/news-release/2023/01/11/2586939/0/en/Intellia-Therapeutics-Awarded-Innovation-Passport-in-the-United-Kingdom-for-NTLA-2002-an-Investigational-Genome-Editing-Treatment-for-Hereditary-Angioedema.html
https://endpts.com/intellia-plots-pivotal-trials-for-lead-programs-as-it-lays-out-key-objectives/
https://www.globenewswire.com//news-release/2023/01/05/2583572/0/en/Intellia-Therapeutics-Highlights-Strategic-Priorities-and-Anticipated-2023-Key-Milestones.html
https://www.forbes.com/sites/greatspeculations/2022/12/19/will-intellia-therapeutics-stock-rebound-after-a-31-fall-in-a-month/
Market Place
Share 
